Jefferies analyst David Windley upgraded Humana (HUM) to Buy from Hold with a price target of $313, up from $253. The firm upped the company’s earnings estimates for 2026 and 2027 following an analysis of Humana’s Stars diversification effort. Humana’s voluntary churn and “significant” 2026 share gains should drive even higher Stars diversification than previously anticipated, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana management to meet with KeyBanc
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Humana Reaffirms Earnings Guidance for December 2025
- Humana to reaffirm FY25 adjusted EPS view $17.00, consensus $17.16
- Trump Weekly: White House postpones healthcare proposal after backlash